T细胞疗法-话题@MedSci

#T细胞疗法#

95篇内容 | 3220人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1478016, encodeId=f3a114e8016ab, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=Blood：CLL细胞会损害CD8+ T细胞的线粒体适应性、降低CAR T细胞疗法疗效！, objectType=article, longId=166207, objectId=9c7f16620ea9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c7f16620ea9, replyNumber=0, likeNumber=68, createdTime=2019-05-18, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c7f16620ea9, moduleTitle=Blood：CLL细胞会损害CD8+ T细胞的线粒体适应性、降低CAR T细胞疗法疗效！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9c7f16620ea9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478015, encodeId=883014e8015de, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=ASGCT：上海斯丹赛公布其装载PD-1拮抗分子CAR-T细胞疗法治疗淋巴瘤患者的临床数据, objectType=article, longId=165949, objectId=e85d1659491a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e85d1659491a, replyNumber=0, likeNumber=75, createdTime=2019-05-14, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e85d1659491a, moduleTitle=ASGCT：上海斯丹赛公布其装载PD-1拮抗分子CAR-T细胞疗法治疗淋巴瘤患者的临床数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e85d1659491a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478014, encodeId=78e414e801492, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=MaxCyte宣布开展基于mRNA的CAR-T细胞疗法的I期临床试验第二批患者给药, objectType=article, longId=165942, objectId=8c7e165942ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c7e165942ca, replyNumber=0, likeNumber=106, createdTime=2019-05-14, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c7e165942ca, moduleTitle=MaxCyte宣布开展基于mRNA的CAR-T细胞疗法的I期临床试验第二批患者给药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c7e165942ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478013, encodeId=f87614e80138d, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=CAR-T细胞疗法公司Autolus计划后续融资1亿美元, objectType=article, longId=164173, objectId=17f41641e3ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=17f41641e3ff, replyNumber=0, likeNumber=69, createdTime=2019-04-14, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=17f41641e3ff, moduleTitle=CAR-T细胞疗法公司Autolus计划后续融资1亿美元, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=17f41641e3ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478012, encodeId=bf9614e801204, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=Autolus的下一代CAR-T细胞疗法更加安全有效, objectType=article, longId=163641, objectId=23b816364145, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=23b816364145, replyNumber=0, likeNumber=65, createdTime=2019-04-06, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=23b816364145, moduleTitle=Autolus的下一代CAR-T细胞疗法更加安全有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=23b816364145)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478011, encodeId=221c14e80119c, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=Blood：嵌合抗原受体T细胞疗法的临床效果、管理和神经毒性, objectType=article, longId=163410, objectId=3d86163410a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d86163410a2, replyNumber=0, likeNumber=99, createdTime=2019-04-03, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d86163410a2, moduleTitle=Blood：嵌合抗原受体T细胞疗法的临床效果、管理和神经毒性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d86163410a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478010, encodeId=941114e8010e0, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=同种异体CAR-T细胞疗法开发公司Cellectis同时在巴黎和美国建立大型厂房, objectType=article, longId=162211, objectId=77bb16221122, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77bb16221122, replyNumber=0, likeNumber=73, createdTime=2019-03-14, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77bb16221122, moduleTitle=同种异体CAR-T细胞疗法开发公司Cellectis同时在巴黎和美国建立大型厂房, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=77bb16221122)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478009, encodeId=06f114e80090e, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=Precision Biosciences为开发同种异体CAR-T细胞疗法筹集1亿美元资金, objectType=article, longId=161812, objectId=07b61618129e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=07b61618129e, replyNumber=0, likeNumber=120, createdTime=2019-03-08, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=07b61618129e, moduleTitle=Precision Biosciences为开发同种异体CAR-T细胞疗法筹集1亿美元资金, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=07b61618129e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478008, encodeId=19a214e8008c5, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=Cell Medica获资助870万美元用于CAR-NKT细胞疗法的癌症治疗研究, objectType=article, longId=161428, objectId=a4b81614287d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a4b81614287d, replyNumber=0, likeNumber=70, createdTime=2019-03-02, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a4b81614287d, moduleTitle=Cell Medica获资助870万美元用于CAR-NKT细胞疗法的癌症治疗研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a4b81614287d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478007, encodeId=5ef214e800768, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=Blood：CD19 CAR-T细胞疗法明显提高ALL患者的无事件存活期, objectType=article, longId=159703, objectId=2590159e03b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2590159e03b3, replyNumber=0, likeNumber=80, createdTime=2019-02-11, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2590159e03b3, moduleTitle=Blood：CD19 CAR-T细胞疗法明显提高ALL患者的无事件存活期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2590159e03b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478006, encodeId=b8ef14e800618, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=Lancet oncol：Axicabtagene ciloleucel（自体抗CD19嵌合抗原受体T细胞疗法）治疗复发性/难治性大B细胞淋巴瘤的长期安全性和疗, objectType=article, longId=155389, objectId=074b15538986, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=074b15538986, replyNumber=0, likeNumber=43, createdTime=2018-12-10, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=074b15538986, moduleTitle=Lancet oncol：Axicabtagene ciloleucel（自体抗CD19嵌合抗原受体T细胞疗法）治疗复发性/难治性大B细胞淋巴瘤的长期安全性和疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=074b15538986)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478005, encodeId=91a014e8005f9, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=NEJM：首次！现货过继性T细胞疗法在临床试验中成功挽救罕见致死性脑感染的癌症患者, objectType=article, longId=151065, objectId=e8d21510656e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e8d21510656e, replyNumber=0, likeNumber=80, createdTime=2018-10-16, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e8d21510656e, moduleTitle=NEJM：首次！现货过继性T细胞疗法在临床试验中成功挽救罕见致死性脑感染的癌症患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e8d21510656e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478004, encodeId=e96c14e8004dd, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=过继性T细胞疗法治疗罕见的脑部感染, objectType=article, longId=151020, objectId=97741510203e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=97741510203e, replyNumber=0, likeNumber=86, createdTime=2018-10-16, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=97741510203e, moduleTitle=过继性T细胞疗法治疗罕见的脑部感染, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=97741510203e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478003, encodeId=7fcc14e8003dd, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=Arthritis Rheumatol：系统性红斑狼疮的过继性调节性T细胞疗法, objectType=article, longId=150300, objectId=f9411503001f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f9411503001f, replyNumber=0, likeNumber=92, createdTime=2018-10-04, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f9411503001f, moduleTitle=Arthritis Rheumatol：系统性红斑狼疮的过继性调节性T细胞疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f9411503001f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478002, encodeId=601d14e80028f, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=诺华CAR-T细胞疗法Kymriah获得加拿大批准上市, objectType=article, longId=148598, objectId=6a66148598f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a66148598f0, replyNumber=0, likeNumber=67, createdTime=2018-09-12, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a66148598f0, moduleTitle=诺华CAR-T细胞疗法Kymriah获得加拿大批准上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a66148598f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478001, encodeId=6da614e800157, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=Regeneron和Bluebird Bio强强联手助力于T细胞疗法, objectType=article, longId=146074, objectId=f21e1460e46b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f21e1460e46b, replyNumber=0, likeNumber=61, createdTime=2018-08-09, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f21e1460e46b, moduleTitle=Regeneron和Bluebird Bio强强联手助力于T细胞疗法, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f21e1460e46b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1478000, encodeId=872914e8000db, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=Cell：CRISPR新一代编辑技术为CAR T细胞疗法提出全新概念, objectType=article, longId=139801, objectId=3718139801c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3718139801c2, replyNumber=0, likeNumber=76, createdTime=2018-06-04, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3718139801c2, moduleTitle=Cell：CRISPR新一代编辑技术为CAR T细胞疗法提出全新概念, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3718139801c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477999, encodeId=b0a814e799955, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=陈文明教授：复发/难治多发性骨髓瘤的诊疗及CAR-T细胞疗法初探, objectType=article, longId=139390, objectId=63731393902c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63731393902c, replyNumber=0, likeNumber=63, createdTime=2018-05-31, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63731393902c, moduleTitle=陈文明教授：复发/难治多发性骨髓瘤的诊疗及CAR-T细胞疗法初探, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63731393902c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477998, encodeId=f9c214e7998e6, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=CAR-T细胞疗法和基因治疗能实现可持续销售吗？, objectType=article, longId=135424, objectId=3315135424ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3315135424ff, replyNumber=0, likeNumber=70, createdTime=2018-04-17, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3315135424ff, moduleTitle=CAR-T细胞疗法和基因治疗能实现可持续销售吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3315135424ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1477997, encodeId=fb4c14e799703, content=<a href='/topic/show?id=bb6f18030a4' target=_blank style='color:#2F92EE;'>#T细胞疗法#</a>, objectTitle=Science：CAR-T细胞疗法新近进展, objectType=article, longId=134951, objectId=58c9134951a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=58c9134951a2, replyNumber=0, likeNumber=84, createdTime=2018-04-13, rootId=0, userName=124984edm24暂无昵称, userId=6bea7392214, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=58c9134951a2, moduleTitle=Science：CAR-T细胞疗法新近进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=58c9134951a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

T细胞疗法

2020-05-29

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

Blood：CLL细胞会损害CD8+ T细胞的线粒体适应性、降低CAR T细胞疗法疗效！

2019-05-18

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

ASGCT：上海斯丹赛公布其装载PD-1拮抗分子CAR-T细胞疗法治疗淋巴瘤患者的临床数据

2019-05-14

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

MaxCyte宣布开展基于mRNA的CAR-T细胞疗法的I期临床试验第二批患者给药

2019-05-14

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

CAR-T细胞疗法公司Autolus计划后续融资1亿美元

2019-04-14

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

Autolus的下一代CAR-T细胞疗法更加安全有效

2019-04-06

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

Blood：嵌合抗原受体T细胞疗法的临床效果、管理和神经毒性

2019-04-03

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

同种异体CAR-T细胞疗法开发公司Cellectis同时在巴黎和美国建立大型厂房

2019-03-14

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

Precision Biosciences为开发同种异体CAR-T细胞疗法筹集1亿美元资金

2019-03-08

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

Cell Medica获资助870万美元用于CAR-NKT细胞疗法的癌症治疗研究

2019-03-02

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

Blood：CD19 CAR-T细胞疗法明显提高ALL患者的无事件存活期

2019-02-11

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

Lancet oncol：Axicabtagene ciloleucel（自体抗CD19嵌合抗原受体T细胞疗法）治疗复发性/难治性大B细胞淋巴瘤的长期安全性和疗

2018-12-10

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

NEJM：首次！现货过继性T细胞疗法在临床试验中成功挽救罕见致死性脑感染的癌症患者

2018-10-16

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

过继性T细胞疗法治疗罕见的脑部感染

2018-10-16

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

Arthritis Rheumatol：系统性红斑狼疮的过继性调节性T细胞疗法

2018-10-04

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

诺华CAR-T细胞疗法Kymriah获得加拿大批准上市

2018-09-12

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

Regeneron和Bluebird Bio强强联手助力于T细胞疗法

2018-08-09

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

Cell：CRISPR新一代编辑技术为CAR T细胞疗法提出全新概念

2018-06-04

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

陈文明教授：复发/难治多发性骨髓瘤的诊疗及CAR-T细胞疗法初探

2018-05-31

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

CAR-T细胞疗法和基因治疗能实现可持续销售吗？

2018-04-17

124984edm24暂无昵称 (审核中...)

前往app查看评论内容

#T细胞疗法#

Science：CAR-T细胞疗法新近进展

2018-04-13

科室
- - 订阅+
  - 更多科室
工具
服务